ETF PROAI

SPMDvsXPH

SPDR Portfolio S&P 400 Mid Cap ETF against SPDR S&P Pharmaceuticals ETF — the fee, the flows, the book, and a year head-to-head.

One year, growth of $100
SPMD 112XPH 132Oct 25Oct 26GROWTH OF $100
Head to head
SPMDXPH
Expense ratio0.030%0.35%
Assets$17.9B$524M
Net flow, 1 month+$207M−$43M
Net flow, 1 year+$2.1B+$271M
Return, YTD+11.0%+13.6%
Return, 1 year+11.9%+31.8%
Avg daily volume1.6M188K
Holdings40141
ListedNov 8, 2005Jun 19, 2006
Options marketYesYes

MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS

THE DESK BRIEF

Flows, fee cuts, and closure risk on the funds you watch — every trading morning.